2. GPCR/G Protein
  3. Endothelin Receptor
  4. Avosentan

Avosentan  (Synonyms: Ro 67-0565; SPP-301)

製品番号: HY-15195 純度: 98.15%
COA 取扱説明書 Technical Support

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Avosentan

Avosentan 構造式

CAS 番号 : 290815-26-8

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 100 在庫あり
Solution
10 mM * 1 mL in DMSO USD 100 在庫あり
Solid
5 mg $95 在庫あり
10 mg $135 在庫あり
25 mg $285 在庫あり
50 mg $490 在庫あり
100 mg $700 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of Avosentan:

Avosentan 関連抗体

Top Publications Citing Use of Products

Endothelin Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
ETA ETB

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure[1][2][3][4].

IC50 & Target[1][2][3][4]

ETA

 

Cellular Effect
Cell Line Type Value Description References
CHO IC50
1.4 1
Compound: 25; Avosentan
Displacement of 125I-ET1 from ETA receptor (unknown origin) expressed in CHO cells
Displacement of 125I-ET1 from ETA receptor (unknown origin) expressed in CHO cells
[PMID: 27321813]
CHO IC50
1.4 1
Compound: 25; Avosentan
Displacement of 125I-ET1 from ETA receptor (unknown origin) expressed in CHO cells
Displacement of 125I-ET1 from ETA receptor (unknown origin) expressed in CHO cells
[PMID: 27321813]
体外実験

Avosentan (0.01-1 μM, 30 min) has no direct effect on quiescent vessels but has a strong inhibitory effect on the endothelin-1 induced contractions in isolated porcine ciliary arteries and shows stronger effect in endothelium-denuded vessels[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Avosentan 関連抗体
体内実験

Avosentan (Incremental doses of 0.003-3 mg/kg, i.v., at 30-min intervals) inhibits ETB receptor-mediated effects and consequently leads to acute fluid retention in anesthetized rats[1].
Avosentan (0.1-100 mg/kg, i.g., single dose or once daily for 5 weeks) is protective in hypertensive nephropathy at doses not causing fluid retention in rats[3].
Avosentan (0.003%-0.3%, topically applied to the glaucomatous eye, twice daily for 5 days) reduces intraocular pressure (IOP) in glaucomatous monkey eyes in a dose-dependent manner[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Renal excretory function assay established male Sprague-Dawley (SD) rats (12-14 weeks)[1]
Dosage: Incremental doses of 0.003, 0.03, 3 mg/kg, BQ-788 (HY-15894A) was administered 30 min after the highest dose
Administration: Intravenous administration (i.v.), at 30-min intervals
Result: Decreased urine output and fractional excretion of water in a concentration-dependent manner.
Returned sodium excretion to control values and slightly decreased mean arterial pressure (MAP)
Did not further decrease urine output or water excretion and was without effect.
Significantly decreased hematocrite.
Animal Model: Hypertensive nephropathy model established male double transgenic rats (dTGR) with human angiotensinogen and renin genes[3]
Dosage: 0.1, 1, 10, 100 mg/kg (single dose) and 10 mg/kg (long-term)
Administration: Oral gavage (i.g.), single dose or once daily for 5 weeks
Result: Caused 18.3% decrease in diuresis, 8.3% drop in hematocrit at 100 mg/kg and No significant fluid retention at 10 mg/kg.
Reduced proteinuria and significantly lowered the scores of renal glomerular fibrosis and other damages after 5-week treatments.
Significantly increased survival rate combined with Valsartan (HY-18204).
Animal Model: IOP model established in adult female cynomolgus monkeys each weighing 3-5 kg, in which glaucoma had been induced unilaterally by repeated diode laser photocoagulation of the mid-trabecular meshwork[4]
Dosage: Topically applied to the glaucomatous eye, twice daily for 5 days
Administration: Oral gavage (i.g.), single dose or once daily for 5 weeks
Result: Significantly reduced IOP only at 2 hrs after the first dose, and at 2 and 3 hrs after the 9th dose.
Produced a longer duration of action at 0.03% and 0.3% concentrations.
No anterior chamber cellular response was observed in any eye during the 5 days of treatment by slit-lamp examination.
臨床実験
分子量

479.51

分子式

C23H21N5O5S
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

COC1=C(OC(C(NS(C2=NC=C(C=C2)C)(=O)=O)=NC(C3=CC=NC=C3)=N4)=C4OC)C=CC=C1
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 6.67 mg/mL (13.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0855 mL 10.4273 mL 20.8546 mL
5 mM 0.4171 mL 2.0855 mL 4.1709 mL
10 mM 0.2085 mL 1.0427 mL 2.0855 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0855 mL 10.4273 mL 20.8546 mL 52.1366 mL
5 mM 0.4171 mL 2.0855 mL 4.1709 mL 10.4273 mL
10 mM 0.2085 mL 1.0427 mL 2.0855 mL 5.2137 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Avosentan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Avosentan290815-26-8Ro 67-0565 SPP-301SPP301SPP 301SPP-301Endothelin ReceptorHypertensive nephropathyEndothelin receptor antagonistAngiotensin receptor antagonistFluid retention Glaucoma monkeyIntraocular pressureIsolated ciliary arteriesMyographyInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Avosentan
製品番号:
HY-15195
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.